as of 06-05-2026 12:21pm EST
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.
| Founded: | 1997 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 247.1M | IPO Year: | 2016 |
| Target Price: | $110.00 | AVG Volume (30 days): | 25.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $6.80 - $97.97 | Next Earning Date: | 05-22-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | -72.22% | Revenue Growth (next year): | 223.84% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
10% Owner
Avg Cost/Share
$64.43
Shares
1,563
Total Value
$100,711.75
Owned After
490,000
SEC Form 4
10% Owner
Avg Cost/Share
$72.00
Shares
39,665
Total Value
$2,855,880.00
Owned After
490,000
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Opaleye Management Inc. | SLGL | 10% Owner | May 20, 2026 | Buy | $64.43 | 1,563 | $100,711.75 | 490,000 | |
| Opaleye Management Inc. | SLGL | 10% Owner | Mar 24, 2026 | Buy | $72.00 | 39,665 | $2,855,880.00 | 490,000 |
See how SLGL stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "SLGL Sol-Gel Technologies Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.